Treatment of hepatitis C virus and human immunodeficiency virus coinfection: From large trials to real life

Journal of Viral Hepatitis

Volumn 13, Issue 10, 2006, Pages 678-682

  Cacoub, P ^a   Rosenthal, E ^b   Halfon, P ^c   Sene, D ^a   Perronne, C ^d   Pol, S ^e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c Laboratoire Alphabio   (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

HCV; HIV; Treatment

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DRUG USE; EUROPE; FEMALE; FOLLOW UP; FRANCE; GENOTYPE; HEALTH CARE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER INJURY; MALE; MEDICAL INFORMATION; MEDICAL SPECIALIST; MENTAL DISEASE; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PHYSICIAN; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT CONTRAINDICATION; TREATMENT REFUSAL; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; FRANCE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; RNA, VIRAL; VIRAL LOAD;

EID: 33748754359     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00740.x     Document Type: Article

References (30)

1. Cacoub P, Geffray L, Rosenthal E et al. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997. Clin Infect Dis 2001; 32: 1207-1214.
2. Rosenthal E, Poiree M, Pradier C et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803-1809.
3. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492-497.
4. Jaggy C, von Overbeck J, Ledergerber B et al. Mortality in the Swis Mortality in the Swiss HIV cohort study (SHCS) and the Swiss general population. Lancet 2003; 362: 877-878.
5. Tedaldi EM, Baker RK, Moorman AC et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 36: 363-367.
6. Martin-Carbonero L, Soriano V, Valencia ME, Lopez M, Gonzalez-Lahoz J. Impact of chronic viral hepatitis on hospital admission and mortality in HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1467-1471.
7. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15: 1-4.
8. Sherman KE, Rouster SD, Chung RT. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-837.
9. Anonymous. Premiers résultats du nouveau dispositif de surveillance de l'infection à VIH et situation du sida au 30 septembre 2003. BEH 2004; 24/25: 102-109.
10. Lewden C, Salmon D, Morlat P et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34(1): 121-130.
11. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
12. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
13. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-1499.
14. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
15. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
16. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
17. Chung RT, Andersen J, Volberding P et al. PEG-interferon-alfa-2a plus ribavirin versus interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons. N Engl J Med 2004; 351: 451-459.
18. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon-alfa- 2a plus ribavirin versus interferon-alfa-2a plus ribavirin in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
19. Carrat F, Bani-Sadr F, Pol S et al. A Randomized Controlled Trial of Pegylated Interferon alfa-2b plus Ribavirin versus Standard Interferon alfa-2b plus Ribavirin for Initial Treatment of Chronic Hepatitis C in HIV-infected Patients (RIBAVIC-ANRS HC02). JAMA 2004; 292: 2839-2848.
20. Laguno M, Murillas J, Blanco JL et al. Peginterferon-alfa-2b plus ribavirin versus interferon-alfa-2b plus ribavirin for treatment of HIV-HCV co-infected patients. AIDS 2004; 18: F27-F36.
21. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36(1): 97-100.
22. Fleming CA, Tumilty S, Murray JE, Nunes D. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 2005; 40 (Suppl. 5): S349-S354.
23. Alberti A, Clumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B or C in HIV co-infected patients. J Hepatol 2005; 42(5): 615-624.
24. Seydi M, Morlat P, Bonnet F et al. Effiacy and safety of pegylated interferon plus ribavirin in HIV-infected patients co-infected with HCV in clinical practice: a 32 case observational follow-up. Rev Med Interne 2005; 26(4): 280-287.
25. Myers RP, Benhamou Y, Imbert-Bismut F et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003; 17(5): 721-725.
26. Sterling R, Lissen E, Clumeck N et al. Can routine non-invasive tests predict liver histology in HIV/HCV co-infection? Analysis of Patients Entering the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT). 12th Conference, Boston, MA, USA.
27. Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128(2): 343-350.
28. Clanon KA, Johannes Mueller J, Harank M. Integrating treatment for hepatitis C virus infection into an HIV clinic. Clin Infect Dis 2005; 40 (Suppl. 5): S362-S366.
29. Anonymous. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19(3): 1-46.
30. Soriano V, Puoti M, Sulkowski M et al. Care of patients with hepatitis C and HIV coinfection. AIDS 2004; 18: 1-12.